Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 30Lung Neoplasms 30Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Multiple Myeloma 22Breast Neoplasms 20Lymphoma 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Lymphoma, Large B-Cell, Diffuse 14Colorectal Neoplasms 14Pancreatic Neoplasms 11Neoplasm Metastasis 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Mouth Neoplasms 10Glioma 10Glioblastoma 10Burkitt Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Triple Negative Breast Neoplasms 8Sarcoma 8Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Lymphoma, Non-Hodgkin 8Laryngeal Neoplasms 8Carcinoma 8

Interventions

pembrolizumab 4Nivolumab 4fludarabine 3aldesleukin 3Paclitaxel 3Ipilimumab 3Cyclophosphamide 3Carboplatin 3padeliporfin 2atezolizumab 2anlotinib 2Riluzole 2Gemcitabine 2vinflunine 1sipuleucel-T 1relatlimab 1palbociclib 1olaparib 1niraparib 1motexafin gadolinium 1luprolide acetate gel depot 1lenvatinib 1ixabepilone 1cabozantinib 1Therapeutics 1Suspensions 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1Powders 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urogenital Neoplasms × Specimen Handling × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡